Next Article in Journal
Analysis of Medications Returned During a Medication Take-Back Event
Next Article in Special Issue
Use of Etomidate for Rapid Sequence Intubation (RSI) in Pediatric Trauma Patients: An Exploratory National Survey
Previous Article in Journal
Medication Reconciliation at Discharge from Hospital: A Systematic Review of the Quantitative Literature
Previous Article in Special Issue
Antimicrobial Renal Injury in a Pediatric Intensive Care Unit: β-Lactams vs. Vancomycin
Article Menu

Export Article

Open AccessOpinion
Pharmacy 2015, 3(3), 72-78;

Creating a Distinct Medication-Use System for Children at the Point of Care: The Time is Now

Pharmacy Perioperative Care and Paediatrics, Regional Pharmacy Services—North Alberta Health Services, Royal Alexandra Hospital, 10240 Kingsway, NW, S103.5 ATC, Edmonton, AB T5H 3V9, Canada
Military and Veterans' Clinical Rehabilitation Research, University of Alberta, Edmonton, AB T6G 2G4, Canada
Author to whom correspondence should be addressed.
Academic Editor: Sandra Benavides Caballero
Received: 23 March 2015 / Revised: 20 May 2015 / Accepted: 17 June 2015 / Published: 25 June 2015
(This article belongs to the Special Issue Pharmacy Paediatrics)
Full-Text   |   PDF [345 KB, uploaded 25 June 2015]


Children need a distinct medicines-use system designed explicitly for them since their continued inclusion in a system of prescription processing developed for adults generates insoluble risk points and workarounds. The American Academy of Pediatrics (AAP), in its policy statement released by the AAP Committee on Drugs in early 2014 about off-label use in children, posits that federal legislation on increased drug testing in children has been effective, as “there have been over 500 pediatric-specific labeling changes.” However, the AAP’s position has not changed materially since the original 2002 policy statement. Indeed, other health professionals, their organizations, or affiliated practice-based research network (PBRNs) mechanisms continue to be excluded from consideration, collaboration, or even honorable mention. It is noteworthy that most of the 500 labeling changes made since 1997 have addressed the scientific validity of indications for medication use in pediatric population without regard to pharmacotherapy formulation or monitoring. Medication use in children continues to be associated with an unacceptably high rate of adverse events, morbidity, and death. Children should no longer be “shoehorned” into the adult medication-use system, which faces challenges in addressing even the adult population’s needs. The time is now to design a multi-phasic, systematic approach to the pharmacotherapy of children. This paper will argue for the establishment of a distinct medication use system for children, a trans-disciplinary system designed thoughtfully and intentionally, not by convention, consensus, or imitation. View Full-Text
Keywords: AAP Committee on Drugs; medication-use system; off-label; pediatrics; pharmacotherapy AAP Committee on Drugs; medication-use system; off-label; pediatrics; pharmacotherapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

II, R.P.; Cernak, I. Creating a Distinct Medication-Use System for Children at the Point of Care: The Time is Now. Pharmacy 2015, 3, 72-78.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmacy EISSN 2226-4787 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top